Abstract: Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target.

Abstract: Disclosed herein, are compositions comprising one or more a molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

Abstract: Disclosed are antigen delivery systems comprising a nanoparticle, wherein the nanoparticle is surface-modified with a cancer-specific cell targeting peptide and comprises an immunogenic HLA class I restricted peptide, wherein the HLA class I restricted peptide is a vaccine-dependent, immunogenic HLA class I restricted peptide; methods of treating a subject having cancer comprising administering said delivery systems; methods of killing cancer cells comprising contacting cancer cells delivery systems, wherein upon entry of the liposome into the cancer cells, the cancer cells present said peptide from said delivery system, wherein the cancer cells generate an immune response said peptide, and wherein the immune response to said peptide targets and kills the cancer cells presenting the vaccine-dependent, peptide; methods of generating a non-cancer secondary immune response that targets cancer cells comprising administering said delivery systems to a subject having cancer cells.

Abstract: Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

Abstract: Disclosed herein are MTS peptides or targeting peptides. Disclosed are MTS peptides comprising the amino acid sequence of any one of SEQ ID NOs: 1- 12. Disclosed are compositions comprising a peptide, wherein the peptide comprises a first MTS peptide conjugated to a cargo. Also disclosed are methods of using the MTS peptides. For example, disclosed are methods of transporting cargo to the CNS comprising administering one or more of the disclosed compositions to a subject in need thereof, wherein the peptide conjugated to cargo enters the CNS.

Abstract: Disclosed are compositions comprising a nucleic acid sequence conjugated to one or more MGS peptides. Disclosed are methods of modifying gene expression of a gene of interest comprising administering to a cell a composition comprising a nucleic acid sequence conjugated to one or more MGS peptides, wherein the nucleic acid sequence binds to the RNA transcribed from the gene of interest, the gene of interest or a sequence upstream of the gene of interest. Disclosed are methods of targeting a gene of interest in an intracellular target comprising administering to a cell a composition comprising a nucleic acid sequence conjugated to one or more MGS peptides, wherein the MGS peptide targets the intracellular target, wherein the nucleic acid sequence binds to the RNA transcribed from the gene interest in an intracellular target.

Abstract: Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.

Abstract: Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target.

Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.

Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.

Abstract: Various embodiments of the present invention provide both apparatus and method for the patterning of cells onto non-adhesive substrates and the controlled regulation of cells through the use of photoactivated cellular morphogenic factors.

Abstract: Various embodiments of the present invention provide both apparatus and method for the patterning of cells onto non-adhesive substrates and the controlled regulation of cells through the use of photoactivated cellular morphogenic factors.